For multiple uses, we suggest aliquoting the stock solution prior to freezing. Bring the solution to room temperature before opening. Make further dilutions using sterile PBS. After reconstituted dilute further with sterilized PBS.
Inhibition of NLRP3
Read Publications using NBP2-30141 in the following applications:
Reconstitute dilute further with sterilized PBS. Make a stock solution of 25 mg/ml of the NLRP3 inhibitor in high purity DMSO (>99.9%).
Alternate Names for Glybenclamide (NLRP3 Inhibitor)
Glybenclamide, also known as glyburide, is an ATP-sensitive potassion channel inhibitor. It has been shown to inhibit various biological processes including PAMP and DAMP-induced activation of the NRLP3 inflammasome as well as the activation of the inflammasome by crystalline substances. Although the mechanism remains to be fully elucidated, evidence suggests that this inhibitor acts downstream of the P2X7 receptor but upsteam of NLRP3. It also blocks maturation of caspase-1 and pro-IL-1b; this occurs through inhibition of K+ efflux. Glybenclamide/Glyburide has a number of additional functions besides blocking. For example, in cultured cells it has been shown to enhance insulin action and stimulates the synthesis of glucose transporters. In this regard, it has gained recognition for studying the mechanisms of Type II diabetes. Researchers are encouraged to consult the published literature regarding additional information about how glybenclamide perturbs biological processes.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Inhibitors are guaranteed for 1 year from date of receipt.
Publications for Glybenclamide Inhibitor (NBP2-30141)(3)
We have publications tested in 2 confirmed species: Human, Mouse.
We have publications tested in 1 application: InhibAct.